drugset / Trial / NCT05308875
Efficacy and Safety Evaluation of PD1-BCMA-CART
Unknown
9 enrolled
Bioray Laboratories
The First Affiliated Hospital of Zhengzhou University · collab
NaSequentialOpen-labelTreatment
Summary
This trial aims to evaluate the safety and efficacy of PD1-BCMA-CART in treating patients with relapsed or refractory multiple myeloma.
Timeline
- Start
- 2024-03-01
- Primary completion
- 2025-01-01
- Completion
- 2025-10-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | PD1-BCMA-CART | Cell therapy | 500000 cells/kg | Intravenous |
| Subject | PD1-BCMA-CART | Cell therapy | 2e+06 cells/kg | Intravenous |